NL-OMON35085RecruitingPhase 2
A double blind, randomized, parallel, study to assess the effects of aliskiren/amlodipine and amlodipine monotherapy on ankle foot volume (AFV) in patients naïve to trial drugs with mild to moderate hypertension. - Effect of SPA on AFV
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- ovartis
- Enrollment
- 88
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •- Male or female 18-75 yrs old
- •- Mild to moderate hypertension
- •- Amlopdipine naïve
- •- Body mass index (BMI) must be 18-32 kg/m2
Exclusion Criteria
- •- Inability of the subjects to switch from all prior antihypertensive medications
- •- Severe hypertension at screening or baseline.
- •- Heart failure
- •- T1DM / T2DM
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A double blind, randomized, parallel study to assess the effects of aliskiren/amlodipine and amlodipine monotherapy on ankle foot volume (AFV) in patients naïve to trial drugs with mild to moderate hypertensioMedDRA version: M15Level: LLTClassification code 10020772Term: <Manually entered code. Term in E.1.1>hypertensionEUCTR2009-014359-63-NLovartis Pharma Services AG88
Completed
Not Applicable
Continuous TAP blocks for major gynaecological surgeryPain after major gynaecological oncology surgeryCancerISRCTN60295543Joint Research Governance Office, Imperial College Healthcare Trust19
Active, not recruiting
Not Applicable
Efficacy and safety of Sarilumab and Adalimumab monotherapy in patients with Rheumatoid ArthritisRheumatoid ArthritisEUCTR2014-002541-22-GBsanofi-aventis recherche & développement340
Active, not recruiting
Phase 1
Efficacy and safety of Sarilumab and Adalimumab monotherapy in patients with Rheumatoid ArthritisMedDRA version: 17.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2014-002541-22-ESsanofi-aventis recherche & développement340
Active, not recruiting
Phase 1
Efficacy and safety of Sarilumab and Adalimumab monotherapy in patients with Rheumatoid ArthritisMedDRA version: 20.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2014-002541-22-DEsanofi-aventis recherche & développement540